Revium Rx RVRC
OTC RVRC
$1.43 +0.00 (+0.00%)
At close: Nov 9, 2026 · 4:00 PM EST

Revium Rx (RVRC) Income from Continuing Operations (2025 - 2026)

Updated

Revium Rx (RVRC) recorded Income from Continuing Operations of -$732,000 in Q2 2026.

Analysis

Revium Rx (RVRC) Income from Continuing Operations (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 210.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.22 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.80 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 2.43 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.25 Bn
10 Revium Rx 86.84 Mn 75.21 Mn - -732,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -732,000.00
Mar 31, 2026 739,000.00
Jun 30, 2025 -938,000.00
Mar 31, 2025 737,000.00
API Access

Revium Rx Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=RVRC&period=max&api_key=YOUR_API_KEY